Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

Fig. 3

Overall survival according to anti-EGFR/anti-VEGF based therapy and sidedness in patients without potentially curative metastasectomy. Kaplan-Meier curves for overall survival in right-sided (a) and left-sided (b) mCRC patients receiving anti-EGFR based or anti-VEGF based front-line therapy, excluding patients who had undergone potentially curative metastasectomy. HR is hazard ratio, 95% confidence interval in brackets

Back to article page